Marshall Wace, LLP Nu Cana PLC Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020
SELL
$4.02 - $9.05 $264,451 - $595,345
-65,784 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$5.55 - $8.48 $289,038 - $441,629
52,079 Added 380.0%
65,784 $401,000
Q3 2019

Nov 14, 2019
BUY
$6.95 - $10.71 $95,249 - $146,780
13,705 New
13,705 $99,000

Others Institutions Holding NCNA

# of Institutions
1
Shares Held
3.33M
Call Options Held
0
Put Options Held
0
View Full List

About NuCana plc

NCNA Quotes by TradingView
  • Ticker NCNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,196,000
  • Market Cap $64.7M
  • Description
  • NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...
More about NCNA
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email